Abstract:

Objective　To investigate the effect of tizanidine hydrochloride and venlafaxine in the treatment of patients with chronic pain. Methods　One hundred and eight patients with chronic pain treated at Yantai City Yantaishan Hospital from April 2021 to April 2023 were selected for the randomized controlled trial, and were divided into a control group and an observation group by lottery, with 54 cases in each group. There were 32 males and 22 females in the control group; they were (44.64±4.18) years old; their disease course was (1.65±0.57) years; their body mass index was (23.05±1.08) kg/m²; 10 cases had pain on the lumbar, 29 the head, and 15 the limbs. There were 30 males and 24 females in the observation group; they were (44.18±4.03) years old; their disease course was (1.72±0.62) years; their body mass index was (23.15±1.01) kg/m²; 12 cases had pain on the lumbar, 27 the head, and 15 the limbs. The control group took tizanidine hydrochloride, and the observation group tizanidine hydrochloride and venlafaxine. The overall effective rates, scores of pain, depression, anxiety, and sleep quality, quality of life, and adverse reactions were compared between the two groups by χ² and t tests. Results　The total effective rate in the observation group was higher than that in the control group [94.44% (51/54) vs. 79.63% (43/54); χ²=5.252; P<0.05]. The pain scores after 2 weeks', 4 weeks' and 3 months' treatment in the observation group were lower than those in the control group (3.54±0.52 vs. 4.42±1.01, 2.24±0.48 vs. and 3.05±0.84, 1.98±0.36 vs. 3.45±0.79; t=5.692, 6.152, and 12.442; all P<0.05). After the treatment, the scores of depression, anxiety, and sleep quality in the observation group were lower than those in the control group (4.82±1.02 vs. 7.42±1.42, 4.10±0.84 vs. 7.05±1.03, and 5.53±1.06 vs. 8.42±1.84; t=10.927, 16.310, and 10.001; all P<0.05). After the treatment, the scores of somatic function, psychological function, social function, physical life status, and overall quality of life in the observation group were higher than those in the control group (82.52±8.48 vs. 75.45±7.19, 81.19±8.27 vs. 74.49±7.22, 82.82±8.51 vs. 75.62±7.34, 80.05±8.28 vs. 72.52±7.66, and 81.69±8.28 vs. 75.44±7.34; t=4.672, 4.484, 4.707, 4.905, and 4.150; all P<0.05). There was no statistical difference in the incidence rate of adverse reactions between the observation group and the control group [9.26% (5/54) vs. 7.41% (4/54); χ²=0.121; P=0.727]. Conclusion　Tizanidine hydrochloride and venlafaxine in the treatment of patients with chronic pain is effective and safe, and can relieve their depression and anxiety and improve their sleep quality and quality of life.

Key words: Chronic pain,  , Tizanidine,  , Venlafaxine,  , Pain level,  , Depression,  , Anxiety,  , Adverse reactions

摘要：

目的　探讨盐酸替扎尼定联合文拉法辛治疗慢性疼痛患者的效果。方法　选取2021年4月至2023年4月烟台市烟台山医院收治的108例慢性疼痛患者进行随机对照试验。采用抽签法将其分为对照组和观察组，各54例。对照组男32例，女22例，年龄（44.64±4.18）岁，病程（1.65±0.57）年，体重指数（BMI）（23.05±1.08）kg/m2，疼痛位置：腰部10例，头部29例，四肢15例。观察组男30例，女24例，年龄（44.18±4.03）岁，病程（1.72±0.62）年，BMI（23.15±1.01）kg/m2，疼痛位置：腰部12例，头部27例，四肢15例。对照组盐酸替扎尼定治疗，观察组盐酸替扎尼定联合文拉法辛治疗。比较两组总有效率、疼痛评分、抑郁评分、焦虑评分、睡眠质量评分、生活质量及不良反应。采用χ2检验和t检验进行统计分析。结果　观察组总有效率高于对照组［94.44%（51/54）比79.63%（43/54）；χ2=5.252，P<0.05］。观察组治疗2周、治疗4周及治疗后3个月疼痛评分均低于对照组［（3.54±0.52）分比（4.42±1.01）分、（2.24±0.48）分比（3.05±0.84）分、（1.98±0.36）分比（3.45±0.79）分；t=5.692、6.152、12.442，均P<0.05）］。治疗后，观察组抑郁、焦虑、睡眠质量评分均低于对照组［（4.82±1.02）分比（7.42±1.42）分、（4.10±0.84）分比（7.05±1.03）分、（5.53±1.06）分比（8.42±1.84）分；t=10.927、16.310、10.001，均P<0.05］。治疗后，观察组躯体功能、心理功能、社会功能、物质生活状态、总体生活质量评分均高于对照组［（82.52±8.48）分比（75.45±7.19）分、（81.19±8.27）比（74.49±7.22）分、（82.82±8.51）分比（75.62±7.34）分、（80.05±8.28）分比（72.52±7.66）分、（81.69±8.28）分比（75.44±7.34）分；t=4.672、4.484、4.707、4.905、4.150，均P<0.05］。观察组与对照组不良反应发生率分别为9.26%（5/54）、7.41%（4/54），差异无统计学意义（χ2=0.121，P=0.727）。结论　盐酸替扎尼定联合文拉法辛治疗慢性疼痛患者效果较好，不良反应少，可缓解患者抑郁和焦虑情绪，提高患者睡眠质量和生活质量。

关键词: 慢性疼痛, 替扎尼定, 文拉法辛, 疼痛程度, 抑郁, 焦虑, 不良反应